`Patent 7,772,209
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`SANDOZ INC.,
`Petitioner,
`
`v .
`
`ELI LILLY AND COMPANY,
`Patent Owner.
`
`Case IPR2016-00318
`Patent 7,772,209
`
`PETITIONER SANDOZ INC.’S
`UPDATED MANDATORY NOTICES
`PURSUANT TO 37 C.F.R. § 42.8
`
`
`
`Case IPR2016-00318
`Patent 7,772,209
`
`A. Real Party-In-Interest (UNCHANGED)
`
`Sandoz Inc. is the real party-in-interest for the instant petition.
`
`B. Related Matters (UPDATED)
`
`1. Related Litigations
`
`Petitioner is not aware of any reexamination certificates or pending
`
`prosecution concerning the ’209 patent. Petitioner is a defendant in the following
`
`litigation involving the ’209 patent: Eli Lilly & Co. v. Sandoz Inc., No. 1:14-cv-
`
`2008 (S.D. Ind., filed December 5, 2014) (“Sandoz Litigation”). Sandoz has timely
`
`filed this petition pursuant to 35 U.S.C. § 315(b) within one year of the date “on
`
`which the petitioner . . . [was] served with [the] complaint alleging infringement of
`
`the patent” – December 15, 2014. Ex. 1053, Return of Service. The Patent Owner
`
`has also asserted the ’209 patent in the following additional litigations in which
`
`Petitioner was not and is not a party: Eli Lilly & Co. v. Teva Parenteral Medicines,
`
`Inc., No. 1:10-cv-1376 (S.D. Ind., filed October 29, 2010) (“Teva Litigation”); Eli
`
`Lilly & Co. v. APP Pharmaceuticals, LLC, No. 1:11-cv-942 (S.D. Ind., filed July
`
`15, 2011); Eli Lilly & Co. v. Accord Healthcare, Inc., USA, No. 1:12-cv-86 (S.D.
`
`Ind., filed January 20, 2012); Eli Lilly & Co. v. Apotex Inc., No. 1:12-cv-499 (S.D.
`
`Ind., filed April 17, 2012); Eli Lilly & Co. v. Accord Healthcare Inc., USA, No.
`
`1:13-cv-335 (S.D. Ind., filed February 28, 2013); Eli Lilly & Co. v. Sun
`
`Pharmaceutical Industries Ltd., No. 1:13-cv-1469 (S.D. Ind., filed September 13,
`
`2
`
`
`
`Case IPR2016-00318
`Patent 7,772,209
`2013); Eli Lilly & Co. v. Glenmark Generics Inc., USA, No. 1:14-cv-104 (S.D.
`
`Ind., filed January 23, 2014); Eli Lilly & Co. v. Nang Kuang Pharmaceutical Co.,
`
`Ltd., No. 1:14-cv-1647 (S.D. Ind., filed October 8, 2014); Eli Lilly & Co. v.
`
`Fresenius Kabi USA, LLC, No. 1:15-cv-96 (S.D. Ind., filed January 23, 2015); Eli
`
`Lilly & Co. v. Mylan Laboratories Ltd., No. 1:15-cv-1083 (S.D. Ind., filed July 10,
`
`2015); Eli Lilly & Co. v. Emcure Pharmaceuticals Ltd., No. 1:15-cv-1244 (S.D.
`
`Ind., filed August 7, 2015); and Eli Lilly & Co. v. Dr. Reddy’s Laboratories, Ltd. et
`
`al., No. 1:16-cv-308 (S.D. Ind., filed Feb. 5, 2016).
`
`Petitioner newly identifies the following additional litigation in which the
`
`Patent Owner has asserted the ’209 patent and in which Petitioner was not and is
`
`not a party: Eli Lilly & Co. v. Biocon Ltd., No. 1:16-cv-469 (S.D. Ind., filed Feb.
`
`26, 2016).
`
`2. Related Proceedings Before the Board
`
`The ’209 patent has also been challenged before the Board in the following
`
`proceedings in which Petitioner was not and is not a party: Accord Healthcare,
`
`Inc., USA v. Eli Lilly & Co., IPR2013-356 (PTAB, filed June 14, 2013); Neptune
`
`Generics, LLC v. Eli Lilly & Co., IPR2016-237 (PTAB, filed November 24, 2015);
`
`and Neptune Generics, LLC v. Eli Lilly & Co., IPR2016-240 (PTAB, filed
`
`November 24, 2015). On October 1, 2013, the Board denied institution of Accord
`
`Healthcare Inc.’s petition in IPR2013-356 because the petition was not filed within
`
`3
`
`
`
`Case IPR2016-00318
`Patent 7,772,209
`the time limit imposed by 35 U.S.C. § 315(b). Neptune Generics, LLC’s
`
`(“Neptune”) two petitions are pending before the Board.
`
`Petitioner newly identifies the following additional proceedings before the
`
`Board in which the ’209 patent has been challenged and in which Petitioner was
`
`not and is not a party: Wockhardt Bio AG v. Eli Lilly & Co., IPR2016-1335
`
`(PTAB, filed June 30, 2016); Wockhardt Bio AG v. Eli Lilly & Co., IPR2016-1337
`
`(PTAB, filed June 30, 2016); Wockhardt Bio AG v. Eli Lilly & Co., IPR2016-1393
`
`(PTAB, filed July 8, 2016); Apotex Inc. & Apotex Corp. v. Eli Lilly & Co.,
`
`IPR2016-1190 (PTAB, filed July 1, 2016); Apotex Inc. & Apotex Corp. v. Eli Lilly
`
`& Co., IPR2016-1191 (PTAB, filed July 1, 2016); Apotex Inc. et al. v. Eli Lilly &
`
`Co., IPR2016-1429 (PTAB, filed July 14, 2016); Teva Pharm. USA, Inc. &
`
`Fresenius Kabi USA, LLC v. Eli Lilly & Co., IPR2016-1340 (PTAB, filed July 1,
`
`2016); Teva Pharm. USA, Inc. & Fresenius Kabi USA, LLC v. Eli Lilly & Co.,
`
`IPR2016-1341 (PTAB, filed July 1, 2016); and Teva Pharm. USA, Inc. &
`
`Fresenius Kabi USA, LLC v. Eli Lilly & Co., IPR2016-1343 (PTAB, filed July 1,
`
`2016). The Petitioners in IPR2016-1335, IPR2016-1190, and IPR2016-1341
`
`requested joinder with IPR2016-237. The Petitioners in IPR2016-1337, IPR2016-
`
`1191, and IPR2016-1343 requested joinder with IPR2016-240. The Petitioners in
`
`IPR2016-1340, IPR2016-1393, and IPR2016-1429 requested joinder with the
`
`instant proceeding.
`
`4
`
`
`
`Case IPR2016-00318
`Patent 7,772,209
`
`C. Lead and Back-Up Counsel (UPDATED)
`
`Lead Counsel
`Ralph J. Gabric (Reg. No. 34,167)
`rgabric@brinksgilson.com
`Brinks Gilson & Lione
`Suite 3600 NBC Tower
`455 Cityfront Plaza Drive
`Chicago IL 60611-5599
`T: 312-321-4200, F: 312-321-4299
`
`Back-Up Counsel
`Laura Lydigsen
`(pro hac vice motion to be filed)
`llydigsen@brinksgilson.com
`Brinks Gilson & Lione
`Suite 3600 NBC Tower
`455 Cityfront Plaza Drive
`Chicago IL 60611-5599
`T: 312-321-4200, F: 312-321-4299
`
`Bryan T. Richardson, Ph.D. (Reg. No.
`70,572)
`brichardson@brinksgilson.com
`Brinks Gilson & Lione
`4721 Emperor Boulevard
`Suite 220
`Durham, NC 27703-8580
`T: 919-998-5700, F: 919-998-5701
`
`Joshua H. James (Reg. No. 72,568)
`jjames@brinksgilson.com
`Postal and Hand-Delivery Address:
`Brinks Gilson & Lione
`Suite 3600 NBC Tower
`455 Cityfront Plaza Drive
`Chicago IL 60611-5599
`T: 312-321-4200, F: 312-321-4299
`
`D. Service Information (UNCHANGED)
`
`Please address all correspondence to the lead and backup counsel at the
`
`contact information above. Petitioner also consents to service by email at
`
`rgabric@brinksgilson.com and llydigsen@brinksgilson.com.
`
`5
`
`
`
`Dated: July 20, 2016
`
`Case IPR2016-00318
`Patent 7,772,209
`Respectfully submitted,
`
`/s/ Ralph J. Gabric
`Ralph J. Gabric (Reg. No. 34,167)
`Laura L. Lydigsen
`Bryan T. Richardson, Ph.D. (Reg. No.
`70,572)
`Joshua H. James (Reg. No. 72,568)
`Brinks Gilson & Lione
`NBC Tower – Suite 3600
`455 N. Cityfront Plaza Dr.
`Chicago, Illinois 60611
`
`6
`
`
`
`CERTIFICATE OF SERVICE
`
`Case IPR2016-00318
`Patent 7,772,209
`
`I hereby certify that true and correct copies of the foregoing Petitioner Sandoz
`Inc.’s Updated Mandatory Notices Under 37 C.F.R. § 42.8 were served on July 20,
`2016 via electronic mail to the following individuals at the email addresses below.
`
`Dov P. Grossman (Reg. No. 72,525)
`Williams & Connolly LLP
`725 Twelfth St. NW
`Washington DC 20005
`Direct Phone: 202-434-5812
`Facsimile: 202-434-5029
`dgrossman@wc.com
`
`David M. Krinsky (Reg. No. 72,339)
`Williams & Connolly LLP
`725 Twelfth St. NW
`Washington DC 20005
`Direct Phone: 202-434-5338
`Facsimile: 202-480-8302
`dkrinsky@wc.com
`
`Adam L. Perlman
`Williams & Connolly LLP
`725 Twelfth St. NW
`Washington DC 20005
`Direct Phone: 202-434-5244
`aperlman@wc.com
`
`James P. Leeds (Reg. No. 35,241)
`Eli Lilly and Company
`Lilly Corporate Center
`Indianapolis, IN 46285
`Direct Phone: 317-276-1667
`Facsimile: 317-277-6534
`leeds_james@lilly.com
`
`
`
`Dated: July 20, 2016
`
`Case IPR2016-00318
`Patent 7,772,209
`
`/s/ Ralph J. Gabric
`Ralph J. Gabric (Reg. No. 34,167)
`Laura L. Lydigsen
`Bryan T. Richardson, Ph.D. (Reg. No.
`70,572)
`Joshua H. James (Reg. No. 72,568)
`Brinks Gilson & Lione
`NBC Tower – Suite 3600
`455 N. Cityfront Plaza Dr.
`Chicago, Illinois 60611